CRISPR Therapeutics AG (CRSP) News
Filter CRSP News Items
CRSP News Results
|Loading, please wait...|
CRSP News Highlights
- 500 - Internal server error
- Over the past 29 days, the trend for CRSP's stories per day has been choppy and unclear. It has oscillated between 1 and 12.
- GENE, AG and VRTX are the most mentioned tickers in articles about CRSP.
Latest CRSP News From Around the Web
Below are the latest news stories about CRISPR Therapeutics AG that investors may wish to consider to help them evaluate CRSP as an investment opportunity.
CRISPR Therapeutics (CRSP) is one of the most-discussed pioneering technology plays on the market today. Indeed, this stock has been better than a 5-bagger for investors who have held CRSP stock for the past five years. For those with a long-term view on this stock, perhaps similar results are in store for the next five years. Gene editing plays are among the hottest in the biotech world today. The company’s market capitalization of nearly $10 billion speaks to the degree of confidence investors have in CRISPR’s ability to generate growing cash flows over time. Some investors may be concerned with the valuation this stock has generated.
CRISPR Therapeutics (NASDAQ: CRSP) has signed a deal with Capsida Biotherapeutics, a gene therapy player specializing in AAV engineering, to carve out a delivery mechanism for the company’s gene-editing technology in familial amyotrophic lateral sclerosis (ALS) and rare neurodegenerative disorder Friedreich’s ataxia. As part of the agreement, Capsida will pick up R&D responsibilities for the ALS program and chip away at capsid design for both programs. Meanwhile, CRISPR will manage R&D for the F
CRISPR Therapeutics and Capsida Biotherapeutics Announce Strategic Collaboration to Develop Gene-Edited Therapies for Amyotrophic Lateral Sclerosis and Friedreich’s Ataxia
- Collaboration leverages expertise and capabilities of both companies towards developing life-changing treatments for severe neurological diseases - ZUG, Switzerland and CAMBRIDGE, Mass. and THOUSAND OAKS, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, and Capsida Biotherapeutics Inc., a biotechnology company dedicated to developing breakthrough gene therapi
Shares of the biotech industry leader have taken a big hit thanks to a clinical development pipeline that hasn't produced any big wins lately.
CRISPR Therapeutics' (CRSP) gene-editing therapy, CTX001, shows consistent and sustained response to treatment in patients with transfusion-dependent beta thalassemia and sickle cell disease.
In our last review of CRISPR Therapeutics on March 23 we were bearish and recommended, "Avoid the long side of CRSP, as the charts and indicators point to the possibility of further steep losses." CRSP declined to a new low in early May, but has strengthened into June. In this daily bar chart of CRSP, below, we can see that prices have held above the chart support in the $90 area from July to early November.
Vertex Pharma and CRISPR Therapeutics Release Data on 22 Patients on Gene-Editing Therapy | #site_titleVertex Pharma and CRISPR Therapeutics Release Data on 22 Patients on Gene-Editing Therapy
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP) reported new data on 22 patients, following up at a minimum of 3 months post gene-editing therapy. CTX001 has shown to provide a consistent and sustained response to treatment. CTX001 is being investigated in two phase ½ clinical trials as a potential therapy for patients that suffer from transfusion dependent beta thalassemia and severe sickle cell disease. Over 40 patients have been dosed across both studies. The data presented today in 22 patients are impressive in both the consistency and durability of effect. These results add to the growing body of evidence that CTX001 may hold the promise for a one-time functional cure for sickle cell disease and beta thalassemia. We are working with urgency...
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP) reported new data on 22 patients, following up at a minimum of 3 months post gene-editing therapy. CTX001 has shown to provide a consistent and sustained response to treatment. CTX001 is being investigated in two phase ½ clinical trials as a potential therapy for patients The post Vertex Pharma and CRISPR Therapeutics Release Data on 22 Patients on Gene-Editing Therapy first appeared on Financial Buzz .
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) and Crispr Therapeutics AG (NASDAQ: CRSP ) have announced new data from Phase 1/2 clinical trials evaluating CTX001 in beta-thalassemia and sickle cell disease. Presenting data from two trials at the European Hematology Association annual meeting, the companies announced that three-month follow-up data of 22 Full story available on Benzinga.com
Thinking about trading options or stock in Crispr Therapeutics, AMC, Atomera, Prothena Corp, or Eli Lilly?
NEW YORK , June 11, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CRSP, AMC, ATOM, PRTA, and LLY. Full story available on Benzinga.com